13 June 2025
Swissmedic: Federal Council approves report in response to a postulate on the monitoring of drug safety
The Federal Council approved the report “Adverse drug reactions. Greater safety and better legal protection” in fulfilment of postulate 20.3456 of the National Council’s Social Security and Health Committee (SSHC-N) dated 14 May 2020. The report shows that Switzerland’s drug safety system is effective. According to the Swiss Federal Audit Office (SFAO) the drug monitoring system of Swissmedic is functioning and effective and Swissmedic also implements risk minimisation measures. Further recommendations and improvements listed in the report were already implemented by the competent authorities.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting